A Phase 3 interventional study of Apremilast and Placebo in Psoriasis, sponsored by Amgen. Completed at 52 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing apremilast in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. apremilast · Psoriasis.
Among the 44 studies testing apremilast in Psoriasis, this one is the 9th largest by enrollment, is one of 6 that started in 2019, is one of 18 in phase 3, and was the 29th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 44 studies testing apremilast in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Syeda Sana Zaman · Sites in Pakistan
Ages 18–60 · Healthy volunteers
University of Athens · Sites in Greece
Ages 18–80 · Healthy volunteers
Amgen
Ages 18–60 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Zarmeen Khawar · Sites in Pakistan
Ages 18–65
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 289 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 103 across the 44 interventional studies. Of the 34 that completed or were terminated, 26 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
61 studies in Psoriasis by Amgen: 1 open now, 1 under way, none of them phase 3. Of 60 finished, 35 (58%) have results posted.
Among the 61 studies in Psoriasis by Amgen, this one is the 21st largest by enrollment of the 49 interventional ones that give a count, is one of 7 that started in 2019, is one of 32 in phase 3, and was the 49th registered.
Amgen’s Psoriasis studies by the year they started, since 2000.
1 of the studies testing apremilast in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing apremilast in Psoriasis, from their registry updates:
Among Amgen’s 61 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G ≥3, moderate or severe).
Approximately 286 subjects with moderate to severe genital psoriasis will be randomized 1:1 to receive either apremilast 30 mg BID or placebo for the first 16 weeks.
The study will consist of four phases:
Double-blind Placebo-controlled Phase - Weeks 0 to 16
Apremilast Extension Phase - Weeks 16 to 32
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
Exclusion Criteria:
The presence of any of the following will exclude a subject from enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
Drug: Apremilast · Other: Placebo
All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study
Drug: Apremilast
Oral
Also known as: CC-10004, Otezla
Oral
Percentage of Participants With a Modified sPGA-G Response at Week 16
The modified sPGA-G is the assessment by the Investigator of the participant's psoriasis lesions' overall disease severity in the genital area at the time of evaluation. The modified sPGA-G is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, plaque elevation, and scaling. A modified sPGA-G response is defined as modified sPGA-G score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the multiple imputation (MI) method. Two-sided 95% confidence intervals (CIs) for the within-group proportions were based on the Wilson-score method.
Time frame: Baseline and Week 16 of the Placebo-controlled Phase
Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16
The sPGA is the assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear), 1 (almost clear), 3 (moderate) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Percentage of Participants With a Genital Psoriasis Itch Numeric Rating Scale (GPI-NRS) Response at Week 16
The GPI-NRS is a self-reported measure where participants were asked to assess their psoriasis symptoms in the genital area and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A GPI-NRS response is defined as ≥ 4 point reduction (improvement) from Baseline. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Change From Baseline in Affected Body Surface Area (BSA) at Week 16
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total BSA). A negative change from Baseline indicates a reduction of affected BSA. Based on mixed-effect model for repeated measures (MMRM) model.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0-30, where 0 represents the best score, and 30 represents the worst health-related quality of life. A negative change from Baseline indicates an improvement in health-related quality of life scores.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Change From Baseline in Genital Psoriasis Symptoms Scale (GPSS) Total Score at Week 16
The GPSS is a self-reported measure where participants were asked to assess each of their psoriasis symptoms (itch, pain, discomfort, stinging, burning, redness, scaling, and cracking) in the genital area and select a number on a scale of 0-10, where 0 represents no symptoms, and 10 represents the worst imaginable. Results from each symptom assessment were summed to generate a total GPSS score ranging from 0 (no genital psoriasis symptoms) to 80 (worst imaginable genital psoriasis symptoms). A negative change from Baseline indicates an improvement in genital psoriasis symptoms.
Time frame: Baseline and Week 16 of the placebo-controlled phase
Participants were enrolled at 49 centers in Belgium, Canada, France, Germany, Italy, and the United States from February 2019 to February 2022.
| Milestone | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast Extension Phase: Apremilast 30 mg |
|---|---|---|---|
| Started | 146 | 143 | 0 |
| Took at least 1 dose of investigational product (ip) | 145 | 143 | 0 |
| Completed | 111 | 119 | 0 |
| Not completed | 35 | 24 | 0 |
| Withdrew: Adverse event | 8 | 10 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 19 | 3 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 7 | 7 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Due to covid-19 control measures | 1 | 0 | 0 |
| Milestone | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast Extension Phase: Apremilast 30 mg |
|---|---|---|---|
| Started | 0 | 0 | 229 |
| Took at least 1 dose of ip | 0 | 0 | 228 |
| Completed | 0 | 0 | 201 |
| Not completed | 0 | 0 | 28 |
| Withdrew: Adverse event | 0 | 0 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 13 |
| Withdrew: Lost to follow-up | 0 | 0 | 7 |
| Withdrew: Miscellaneous | 0 | 0 | 1 |
The modified sPGA-G is the assessment by the Investigator of the participant's psoriasis lesions' overall disease severity in the genital area at the time of evaluation. The modified sPGA-G is a 5-point scale ranging from clear (0), almost clear (1), mild (2), moderate (3), to severe (4), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, plaque elevation, and scaling. A modified sPGA-G response is defined as modified sPGA-G score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the multiple imputation (MI) method. Two-sided 95% confidence intervals (CIs) for the within-group proportions were based on the Wilson-score method.
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With a Modified sPGA-G Response at Week 16 | 19.5 (12.7 to 26.3) | 39.6 (31.2 to 48.0) |
The sPGA is the assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear), 1 (almost clear), 3 (moderate) to 4 (severe), incorporating an assessment of the severity of the 3 primary signs of the disease: erythema, scaling and plaque elevation. An sPGA response is defined as sPGA score of clear (0) or almost clear (1) and with ≥ 2-point reduction from Baseline at Week 16. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 | 6.9 (2.7 to 11.2) | 22.2 (15.0 to 29.3) |
The GPI-NRS is a self-reported measure where participants were asked to assess their psoriasis symptoms in the genital area and select a number on a scale of 0-10, where 0 represents no itch, and 10 represents the worst imaginable itch. A GPI-NRS response is defined as ≥ 4 point reduction (improvement) from Baseline. Missing values were imputed using the MI method. Two-sided 95% CIs for the within-group proportions were based on the Wilson-score method.
| Percentage of participants | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Percentage of Participants With a Genital Psoriasis Itch Numeric Rating Scale (GPI-NRS) Response at Week 16 | 19.6 (11.9 to 27.4) | 47.3 (37.9 to 56.6) |
The BSA is a measurement of involved skin over the whole body. The overall BSA affected by psoriasis is estimated based on the palm area of the participant's hand. The surface area of the whole body is made up of approximately 100 palms or "handprints" (each entire palmar surface or "handprint" equates to approximately 1% of total BSA). A negative change from Baseline indicates a reduction of affected BSA. Based on mixed-effect model for repeated measures (MMRM) model.
| Change in percentage of affected BSA | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Affected Body Surface Area (BSA) at Week 16 | -0.79 ± 0.669 | -4.12 ± 0.664 |
The DLQI is a 10 item questionnaire dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from 0 (not at all) to 3 (very much). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being 0 (not at all), 1 (a little) and 2 (a lot). Total scores have a possible range of 0-30, where 0 represents the best score, and 30 represents the worst health-related quality of life. A negative change from Baseline indicates an improvement in health-related quality of life scores.
| Scores on a scale | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 | -2.6 ± 0.57 | -5.3 ± 0.55 |
The GPSS is a self-reported measure where participants were asked to assess each of their psoriasis symptoms (itch, pain, discomfort, stinging, burning, redness, scaling, and cracking) in the genital area and select a number on a scale of 0-10, where 0 represents no symptoms, and 10 represents the worst imaginable. Results from each symptom assessment were summed to generate a total GPSS score ranging from 0 (no genital psoriasis symptoms) to 80 (worst imaginable genital psoriasis symptoms). A negative change from Baseline indicates an improvement in genital psoriasis symptoms.
| Score on a scale | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg |
|---|---|---|
| Change From Baseline in Genital Psoriasis Symptoms Scale (GPSS) Total Score at Week 16 | -5.3 ± 1.85 | -20.5 ± 1.83 |
Collected over Up to a maximum of 41.4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo-controlled Phase: Placebo | 0/145 (0%) | 2/145 (1.4%) | 39/145 (26.9%) |
| Placebo-controlled Phase: Apremilast 30 mg | 0/143 (0%) | 3/143 (2.1%) | 73/143 (51%) |
| Apremilast Extension Phase: Apremilast 30 mg | 0/229 (0%) | 2/229 (0.9%) | 53/229 (23.1%) |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast Extension Phase: Apremilast 30 mg |
|---|---|---|---|
| Herpes zosterInfections and infestations | 0/145 | 1/143 | 0/229 |
| Clavicle fractureInjury, poisoning and procedural complications | 0/145 | 1/143 | 0/229 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/145 | 1/143 | 0/229 |
| Clostridium difficile infectionInfections and infestations | 1/145 | 0/143 | 0/229 |
| GastroenteritisInfections and infestations | 1/145 | 0/143 | 0/229 |
| Urinary tract infectionInfections and infestations | 1/145 | 0/143 | 0/229 |
| Ankle fractureInjury, poisoning and procedural complications | 1/145 | 0/143 | 0/229 |
| DehydrationMetabolism and nutrition disorders | 1/145 | 0/143 | 0/229 |
| AppendicitisInfections and infestations | 0/145 | 0/143 | 1/229 |
| Actinic keratosisSkin and subcutaneous tissue disorders | 0/145 | 0/143 | 1/229 |
| Event | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Apremilast Extension Phase: Apremilast 30 mg |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 12/145 | 37/143 | 27/229 |
| HeadacheNervous system disorders | 16/145 | 33/143 | 15/229 |
| NauseaGastrointestinal disorders | 11/145 | 32/143 | 17/229 |
| NasopharyngitisInfections and infestations | 12/145 | 12/143 | 11/229 |
The intent-to-treat (ITT) analysis set consisted of all participants who are randomized regardless of whether the participant received investigational product (IP).
| Age, Continuous(Years) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Mean | 46.4 ± 14.38 | 43.5 ± 13.36 | 45.0 ± 13.93 |
| Sex: Female, Male(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Female | 44 | 43 | 87 |
| Male | 102 | 100 | 202 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 18 | 31 |
| Not Hispanic or Latino | 131 | 125 | 256 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 8 | 4 | 12 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 3 | 6 | 9 |
| White | 131 | 131 | 262 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Modified Static Physician Global Assessment of Genitalia (sPGA-G) Score(Participants) | Placebo-controlled Phase: Placebo | Placebo-controlled Phase: Apremilast 30 mg | Total |
|---|---|---|---|
| 3 (Moderate) | 128 | 123 | 251 |
| 4 (Severe) | 18 | 20 | 38 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Feb 2019 to primary completion in Sep 2021, 31 months.
Results were first posted in Dec 2022, 1 year 2 months after primary completion.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 31 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast